Clinical trials: Recurrent GBM
Glioblastoma or Gliosarcoma
DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors
Glioblastoma (GBM) and gliosarcoma (GS) are the most common and aggressive forms of malignant primary brain tumor in adults and can be resistant to conventional therapies.
- Trial name
- TARGET-I (NCT02197169)
- Testing
- Single intratumoral injection of DNX-2401, Interferon-gamma
- Where
- 4 sites in United States
- Volunteers
- 37 people
- Sponsor
- DNAtrix, Inc.
Glioblastoma Multiforme
Evaluating Therapeutic Response to Novo-TTF
This study is to assess the utility of high resolution 3D echo planar magnetic resonance spectroscopy (3D EPSI) in monitoring Novo-TTF response in glioblastoma multiforme (GBM) patients.
- Trial name
- NCT02441322
- Testing
- Novo-TTF
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Brain and Central Nervous System Tumors
Cytotoxic T Cells and Interleukin-2 in Treating Adult Patients With Recurrent Brain Tumors
RATIONALE: Biological therapy uses different ways to stimulate the immune system and stop cancer cells from growing. Cytotoxic T cells combined with interleukin-2 may be an effective treatment for recurrent brain tumors.
- Trial name
- NCT00002572
- Testing
- aldesleukin, muromonab-CD3, therapeutic tumor infiltrating lymphocytes
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of Colorado, Denver
Glioblastoma
A Study to Better Understand the Biological and Molecular Mechanisms Involved in Glioblastoma Recurrence and Progression
BORDEAUX-GLIO is a prospective, monocentric study which will describe the molecular, immune and metabolic pathways involved in the progression and relapse of glioblastoma, using blood and tumor samples from patients who have…
- Trial name
- BORDEAUX-GLIO (NCT07173829)
- Testing
- samples
- Where
- France
- Volunteers
- 45 people
- Sponsor
- University Hospital, Bordeaux
Glioblastoma, GBM
LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients
This trial is an open-label, multicenter, Phase 0/2 trial that will enroll up to 50 participants with recurrent glioblastoma which are schedule for resection.
- Conditions
- Glioblastoma, GBM, Glioma
- Trial name
- NCT04391595
- Testing
- Abemaciclib, LY3214996
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- Nader Sanai
Breast Neoplasms, Ovarian Neoplasms
Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer
The primary purpose of this study is to evaluate the safety, side effects, and dosage for Motexafin Gadolinium given with the chemotherapy drug docetaxel to patients with advanced cancers.
- Conditions
- Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Lung Neoplasms
- Trial name
- NCT00120939
- Testing
- Motexafin Gadolinium
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Pharmacyclics LLC.
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma
Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma
This phase I trial studies the side effects of vaccine therapy when given together with sargramostim in treating patients with malignant glioma.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Giant Cell Glioblastoma
- Trial name
- NCT01250470
- Testing
- Laboratory Biomarker Analysis, Montanide ISA-51/Survivin Peptide Vaccine, Sargramostim
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Roswell Park Cancer Institute
Recurrent Glioblastoma
Sintilimab in Combination With Bevacizumab and Temozolomide in Recurrent Glioblastoma (GBM) Patients
The purpose of this study is to evaluate the efficacy and safety of Sintilimab in combination with Bevacizumab and Temozolomide in subjects with recurrent glioblastoma.
- Trial name
- NCT05638451
- Testing
- Sintilimab plus Bevacizumab and Temozolomide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhujiang Hospital
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme
This phase II trial is studying how well giving vorinostat together with bortezomib works in treating patients with progressive, recurrent glioblastoma multiforme.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Trial name
- NCT00641706
- Testing
- vorinostat, therapeutic conventional surgery, bortezomib
- Where
- 214 sites in United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Glioma
Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00795665
- Testing
- bevacizumab, carmustine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of California, Davis
Brain and Central Nervous System Tumors, Unspecified Adult Solid Tumor, Protocol Specific
Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Calcitriol may help solid tumor cells develop into normal cells.
- Trial name
- NCT00008086
- Testing
- calcitriol, carboplatin
- Where
- United States
- Sponsor
- University of Pittsburgh
Advanced Cancers, Lymphoma
Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma
The goal of this clinical research study is to find the highest tolerable dose of azacitidine that can be given with vorinostat, gemcitabine, busulfan, and melphalan, with a stem cell transplant, and with or without rituximab.
- Trial name
- NCT01983969
- Testing
- Azacitidine, Vorinostat, Gemcitabine
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Brain Stem Glioma
Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors
This phase I/II trial studies lapatinib to see how well it works in treating young patients with recurrent or refractory central nervous system (CNS) tumors.
- Conditions
- Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Ependymoma, Recurrent Childhood Giant Cell Glioblastoma
- Trial name
- NCT00095940
- Testing
- lapatinib ditosylate, therapeutic conventional surgery, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Glioblastoma
Tris-CAR-T Cell Therapy for Recurrent Glioblastoma
This is a Phase 1 study of recurrent glioblastoma locoregional adoptive therapy with autologous peripheral blood T cells lentivirally transduced to express a dual-target, truncated IL7Ra modified chimeric antigen receptor (CAR)…
- Trial name
- NCT05577091
- Testing
- Inverse correlated dual-target, truncated IL7Ra modified CAR -expressing autologous T-lymphocytes.
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Beijing Tiantan Hospital
Brain and Central Nervous System Tumors, Psychosocial Effects of Cancer and Its Treatment
Stress Reduction Program in Patients With Malignant Brain Tumors and Their Family Caregivers
RATIONALE: Yoga, meditation, and breathing exercises may help lower stress and improve quality of life in patients with malignant brain tumors and their family caregivers.
- Trial name
- NCT00376818
- Testing
- exercise intervention, educational intervention, physiologic testing
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Case Comprehensive Cancer Center
Brain and Central Nervous System Tumors, Lymphoma
Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00544284
- Testing
- bortezomib, temozolomide, pharmacological study
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- City of Hope Medical Center
Glioblastoma, Brain Tumor
LITT Followed by Hypofractionated RT for Recurrent Gliomas
The purpose of this study is to evaluate the treatment regimen of using Laser Interstitial Thermal Therapy (LITT) and Hypo-fractionated Radiation Therapy to treat patients with recurrent gliomas.
- Conditions
- Glioblastoma, Brain Tumor, Glioma, Neoplasms
- Trial name
- GCCC 19140 (NCT04181684)
- Testing
- Procedure: LITT, Hypo-Fractionated Radiation Therapy
- Where
- 4 sites in United States
- Volunteers
- 39 people
- Sponsor
- University of Maryland, Baltimore
Recurrent Glioblastoma
Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma
The purpose of this research is to find hidden cancer with an experimental magnetic resonance imaging (MRI) scan called spectroscopic magnetic resonance imaging (sMRI).
- Trial name
- NCT05284643
- Testing
- Intensity Modulated Proton Therapy (IMPT), Bevacizumab
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- University of Miami
Glioblastoma
Post-operative Adjuvant Therapy w/wo GammaTile + Systemic Therapy
To compare surgical tumor removal and GammaTile therapy followed by adjuvant systemic therapy (bevacizumab or lomustine) to surgical tumor removal followed by adjuvant systemic therapy (bevacizumab or lomustine) without GammaTile…
- Trial name
- PATHWAyS (NCT05900908)
- Testing
- Gamma Tile-Surgically Targeted Radiation Therapy (STaRT), Stereotactic Radiation Therapy
- Sponsor
- GT Medical Technologies, Inc.
Brain and Central Nervous System Tumors
Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00352521
- Testing
- bevacizumab, irinotecan, dynamic contrast-enhanced magnetic resonance imaging
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Duke University